Comparative Pharmacology
Head-to-head clinical analysis: DEMEROL versus MORPHABOND ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMEROL versus MORPHABOND ER.
DEMEROL vs MORPHABOND ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meperidine is an opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia, sedation, and euphoria. It also has additional weak actions at kappa and delta receptors.
Morphine is a full opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins. Activation of mu receptors leads to G-protein-coupled inhibition of adenylyl cyclase, decreased cAMP production, closure of voltage-gated calcium channels, and opening of potassium channels. This results in reduced neuronal excitability, inhibition of neurotransmitter release (e.g., substance P, glutamate), and modulation of pain signaling pathways, producing analgesia, euphoria, and sedation.
50-150 mg IM, IV, or SC every 3-4 hours as needed for pain; oral 50-150 mg every 3-4 hours.
15-30 mg orally every 12 hours, titrated to effect; maximum 60 mg per dose or 120 mg daily.
None Documented
None Documented
2.5-4 hours; prolonged in hepatic impairment (7-11 hours) and elderly.
Terminal elimination half-life is approximately 11–13 hours in adults, allowing once-daily dosing for MORPHABOND ER. In hepatic impairment, half-life may be prolonged.
Renal (90% as metabolites and unchanged drug; ~5% unchanged) and biliary/fecal (minor).
Approximately 90% excreted renally as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), with ~10% excreted unchanged. Fecal elimination accounts for <10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic